Early diagnosis and treatment of dengue is critical as epidemics of the disease become larger and more frequent. An estimated 50 to 100 million people contract dengue each year in over 100 countries. Left untreated, patients may experience hemorrhage and shock, leading to death. Recognizing the threat to public health posed by dengue, NIAID is funding nearly 60 dengue research projects, including studies on dengue hemorrhagic fever and dengue shock syndrome, the most severe forms of the disease. NIAID research priorities include effective community-based prevention programs, improved laboratory-based international surveillance, rapid diagnostic tests and therapies, and development of and clinical trials for dengue vaccines.
Experimental Dengue Vaccine Protects All Recipients in Virus Challenge Study—March 16, 2016
Dengue Vaccine Enters Phase 3 Trial in Brazil—Jan. 14, 2016
Media Availability: NIH-Funded Scientists Describe How Mosquitoes Are Attracted to Humans—Dec. 5, 2013
NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial—Jan. 23, 2013
All Dengue Fever News Releases
News from NIAID-Supported Institutions
Last Updated March 16, 2016